Lovastatin Tablet
Product Images NDC 68001-315

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 68001-315). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lovastatin 10mg 100ct Label (Image 01)

Lovastatin Tablets USP 10 mg oral tablet label from BluePoint Laboratories. The label includes the NDC 68001-314-00, dosage strength of 10 mg per tablet, and quantity of 100 tablets. Storage instructions and manufacturing information for Lupin Limited, Goa, India, are also shown along with a barcode.*

FDA Label Image

Lovastatin 20mg 100ct Label (Image 02)

Label for Lovastatin Tablets USP, 20 mg strength, manufactured by BluePoint Laboratories. The label indicates each tablet contains 20 mg of lovastatin with a package count of 100 tablets. It includes storage instructions, dispensing requirements, manufacturer details (Lupin Limited, Goa, India), and a barcode. The design features the BluePoint Laboratories logo and dosage strength prominently in orange.*

FDA Label Image

Lovastatin 40mg 100ct Label (Image 03)

Label for Lovastatin Tablets USP 40 mg oral tablets contains 100 tablets per container. The label shows dosage strength as 40 mg and includes manufacturer information for Lupin Limited, Goa, India, packaging details, and storage instructions. The labeler is BluePoint Laboratories, and the NDC number is partially visible as 68001-316-00.*

FDA Label Image

Lovastatin (Lovastatintabusp Figure 01)

Chemical structure of lovastatin, the active ingredient in Lovastatin tablets by BluePoint Laboratories. The diagram shows the molecular arrangement including rings, bonds, and functional groups characteristic of lovastatin.*

FDA Label Image

Figure 1 (Lovastatintabusp Figure 02)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing the proportion of participants without event over years of follow-up from 0 to about 6. The graph compares Lovastatin and Placebo groups, with Lovastatin showing a higher proportion without events and indicating a 37% risk reduction compared to placebo (p < 0.0001).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.